A PHASE II EVALUATION OF COPANLISIB (BAY 80-6946) (IND #130822), A SELECTIVE INHIBITOR OF PI3KCA, IN PATIENTS WITH PERSISTENT OR RECURRENT ENDOMETRIAL CARCINOMA HARBORING PIK3CA HOTSPOT MUTATIONS
James Hoffman, MD
D'Amour Center for Cancer Care
3350 Main Street
Springfield, MA 01199
The purpose of this study is to test any good and bad effects of the study drug called copanlisib. Researchers hope to learn if the study drug will shrink the cancer by at least one-quarter compared to its present size. Copanlisib has been tested in clinical trials in patients with multiple types of cancer. In this study copanlisib is an experimental treatment of endometrial cancer with PIK3CA hotspot mutation.
Endometrial Cancer which has grown or recurred, Genetic mutation called a PIK3CA Hotspot mutation